Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta

Obstetrics and Gynecology

Volumn 123, Issue 6, 2014, Pages 1256-1261

  Bapat, Priya ^a   Kedar, Reuven ^a   Lubetsky, Angelika ^a   Matlow, Jeremy N ^a   Aleksa, Katarina ^a   Berger, Howard ^a   Koren, Gideon ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; DABIGATRAN ETEXILATE;

ARTICLE; CANADA; CESAREAN SECTION; COTYLEDON; EX VIVO STUDY; FEMALE; FETUS; FETUS CIRCULATION; HUMAN; HUMAN TISSUE; INFORMED CONSENT; LIQUID CHROMATOGRAPHY; MASS SPECTROMETER; MOTHER FETUS RELATIONSHIP; PLACENTA CIRCULATION; PLACENTA PERFUSION; PLACENTAL TRANSFER; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; FEMALE; FETUS; HUMANS; MATERNAL-FETAL EXCHANGE; PERFUSION; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PRODRUGS; PYRIDINES;

EID: 84901633897     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000000277     Document Type: Article

References (31)

1. Royal College of Obstetricians and Gynaecologists. Reducing the risk of thrombosis and embolism during pregnancy and the puerperium. Green-top Guideline No. 37a. London (UK): Royal College of Obstetricians and Gynecologists.
2. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(suppl):e691S-736S.
3. Bremme KA. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol 2003;16:153-68.
4. Dahlman T, Hellgren M, Blomback M. Changes in blood coagulation and fibrinolysis in the normal puerperium. Gynecol Obstet Invest 1985;20:37-44.
5. O'Riordan MN, Higgins JR. Haemostasis in normal and abnormal pregnancy. Best Pract Res Clin Obstet Gynaecol 2003;17: 385-96.
6. Che Yaakob CA, Dzarr AA, Ismail AA, Zuky Nik Lah NA, Ho JJ. Anticoagulant therapy for deep vein thrombosis (DVT) in pregnancy. The Cochrane Database of Systematic Reviews 2010, Issue 6. Art. No.: CD007801. DOI: 10.1002/14651858. CD007801.pub2.
7. Fogerty AE, Connors JM. Management of inherited thrombophilia in pregnancy. Curr Opin Endocrinol Diabetes Obes 2009;16:464-9.
8. Greer IA. Thrombosis in pregnancy: updates in diagnosis and management. Hematol Am Soc Hematol Educ Program 2012; 2012:203-7.
9. James AH. Pregnancy-associated thrombosis. Hematol Am Soc Hematol Educ Program 2009;277-85.
10. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 2000;160:191-6.
11. Hassouna A, Allam H. Anticoagulation of pregnant women with mechanical heart valve prosthesis: a systematic review of the literature (2000-2009). J Coagul Disord 2010;2:81-8.
12. McLintock C. Anticoagulant choices in pregnant women with mechanical heart valves: balancing maternal and fetal risks-the difference the dose makes. Thromb Res 2013;131(suppl 1):S8-10.
13. Bauer KA. Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa. J Thromb Haemost 2011; 9(suppl 1):12-19.
14. Huntington JA, Baglin TP. Targeting thrombin-rational drug design from natural mechanisms. Trends Pharmacol Sci 2003; 24:589-95.
15. Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 2011;123:1436-50.
16. Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 2009;15(SUPPL 1):9S-16S.
17. Eisert WG, Hauel N, Stangier J, Wienen W, Clemens A, van Ryn J. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol 2010;30:1885-9.
18. van Ryn JHN, Waldman L, Wienen W. Dabigatran inhibits both clot-bound and fluid-phase thrombin in vitro: comparison to heparin and hirudin [abstract 570]. Arterioscler Thromb Vasc Biol 2008;28:e136-7.
19. Weitz JI, Leslie B, Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation 1998;97:544-52.
20. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparinantithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-91.
21. Cutts BA, Dasgupta D, Hunt BJ. New directions in the diagnosis and treatment of pulmonary embolism in pregnancy. Am J Obstet Gynecol 2013;208:102-8.
22. Miller RK, Wier PJ, Maulik D, di Sant'Agnese PA. Human placenta in vitro: characterization during 12 h of dual perfusion. Contrib Gynecol Obstet 1985;13:77-84.
23. Derewlany LO, Leeder JS, Kumar R, Radde IC, Knie B, Koren G. The transport of digoxin across the perfused human placental lobule. J Pharmacol Exp Ther 1991;256:1107-11.
24. Pollex E, Lubetsky A, Koren G. The role of placental breast cancer resistance protein in the efflux of glyburide across the human placenta. Placenta 2008;29:743-7.
25. Schneider H, Panigel M, Dancis J. Transfer across the perfused human placenta of antipyrine, sodium and leucine. Am J Obstet Gynecol 1972;114:822-8.
26. Reynolds F, Knott C. Pharmacokinetics in pregnancy and placental drug transfer. Oxf Rev Reprod Biol 1989;11:389-449.
27. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36:386-99.
28. Delavenne X, Moracchini J, Laporte S, Mismetti P, Basset T. UPLC MS/MS assay for routine quantification of dabigatran-a direct thrombin inhibitor-in human plasma. J Pharm Biomed Anal 2012;58:152-6.
29. Pacifici GM, Nottoli R. Placental transfer of drugs administered to the mother. Clin Pharmacokinet 1995;28:235-69.
30. Hartter S, Sennewald R, Nehmiz G, Reilly P. Oral bioavailability of dabigatran etexilate (Pradaxa(-)) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol 2013;75: 1053-62.
31. Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost 2008;6:632-7.